Suppr超能文献

醛固酮与高血压风险。

Aldosterone and the risk of hypertension.

机构信息

Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, 801 Massachusetts Avenue, Suite 470, Boston, MA 02118, USA.

出版信息

Curr Hypertens Rep. 2013 Apr;15(2):102-7. doi: 10.1007/s11906-013-0330-y.

Abstract

Aldosterone, the key hormone in the mineralocorticoid pathway, plays a fundamental role in salt and water homeostasis, blood pressure regulation, and cardiovascular remodeling. Both genomic and nongenomic mechanisms influence aldosterone-induced renal sodium reabsorption. Furthermore, the mineralocorticoid receptors in nonepithelial tissues, including the heart and vascular smooth muscle cells, have recently been discovered. Thus, aldosterone likely has pleiotropic effects that contribute to the modulation of blood pressure. Among patients with hypertension in general, and among those with more severe or resistant hypertension in particular, a higher-than-expected prevalence of primary hyperaldosteronism is noted. Among individuals with resistant hypertension, aldosterone antagonists have also been shown to be effective in lowering blood pressure. Most significantly, recent community-based studies among non-hypertensive individuals in the general population have demonstrated that both higher serum aldosterone concentrations and a higher aldosterone to renin ratio portend a greater risk of developing hypertension. The combination of the aforementioned observations underscores the importance of the mineralocorticoid pathway in the pathogenesis of hypertension.

摘要

醛固酮是盐皮质激素通路的关键激素,在盐和水稳态、血压调节和心血管重塑中起着重要作用。基因组和非基因组机制都影响醛固酮诱导的肾钠重吸收。此外,最近在非上皮组织(包括心脏和血管平滑肌细胞)中发现了矿物质皮质激素受体。因此,醛固酮可能具有多种作用,有助于调节血压。在一般高血压患者中,尤其是在更严重或耐药性高血压患者中,原发性醛固酮增多症的患病率高于预期。在耐药性高血压患者中,醛固酮拮抗剂也已被证明可有效降低血压。最重要的是,最近在普通人群中的非高血压个体的基于社区的研究表明,血清醛固酮浓度较高和醛固酮与肾素比值较高都预示着发生高血压的风险更大。上述观察结果的结合强调了矿物质皮质激素通路在高血压发病机制中的重要性。

相似文献

1
Aldosterone and the risk of hypertension.
Curr Hypertens Rep. 2013 Apr;15(2):102-7. doi: 10.1007/s11906-013-0330-y.
2
Mineralocorticoid antagonism and cardiac hypertrophy.
Curr Hypertens Rep. 2008 Jun;10(3):216-21. doi: 10.1007/s11906-008-0041-y.
3
Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
Curr Hypertens Rev. 2017;13(1):46-56. doi: 10.2174/1573402113666170228151402.
4
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):401-9. doi: 10.1016/j.pcad.2009.12.004.
5
The role of aldosterone antagonists in the management of resistant hypertension.
Curr Hypertens Rep. 2005 Oct;7(5):343-7. doi: 10.1007/s11906-005-0067-3.
6
Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Curr Hypertens Rep. 2005 Jun;7(3):186-92. doi: 10.1007/s11906-005-0008-1.
8
Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
J Hypertens. 2002 Aug;20(8):1465-8. doi: 10.1097/00004872-200208000-00002.
9
Hypertension and the expanding role of aldosterone.
Curr Hypertens Rep. 2006 Jun;8(3):255-61. doi: 10.1007/s11906-006-0059-y.
10
The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
Am J Cardiovasc Drugs. 2007;7(3):151-7. doi: 10.2165/00129784-200707030-00001.

引用本文的文献

2
Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review.
Basic Clin Pharmacol Toxicol. 2025 Aug;137(2):e70080. doi: 10.1111/bcpt.70080.
3
Myocarditis and neutrophil-mediated vascular leakage but not cytokine storm associated with fatal murine leptospirosis.
EBioMedicine. 2025 Feb;112:105571. doi: 10.1016/j.ebiom.2025.105571. Epub 2025 Jan 30.
4
A Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia--R484Q Mutant Mouse.
Int J Mol Sci. 2024 May 7;25(10):5062. doi: 10.3390/ijms25105062.
5
New Prospective Phosphodiesterase Inhibitors: Phosphorylated Oxazole Derivatives in Treatment of Hypertension.
Adv Pharm Bull. 2023 Mar;13(2):399-407. doi: 10.34172/apb.2023.044. Epub 2022 Apr 4.
7
Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data.
Front Endocrinol (Lausanne). 2022 Oct 7;13:1017177. doi: 10.3389/fendo.2022.1017177. eCollection 2022.
8
Dex modulates the balance of water-electrolyte metabolism by depressing the expression of AVP in PVN.
Front Pharmacol. 2022 Aug 23;13:919032. doi: 10.3389/fphar.2022.919032. eCollection 2022.
9
Primary Aldosteronism and Ischemic Heart Disease.
Front Cardiovasc Med. 2022 May 23;9:882330. doi: 10.3389/fcvm.2022.882330. eCollection 2022.
10
Divergent Characteristics of T-Cell Receptor Repertoire Between Essential Hypertension and Aldosterone-Producing Adenoma.
Front Immunol. 2022 May 10;13:853403. doi: 10.3389/fimmu.2022.853403. eCollection 2022.

本文引用的文献

1
Vascular actions of aldosterone.
J Vasc Res. 2013;50(2):89-99. doi: 10.1159/000345243. Epub 2012 Nov 21.
3
Primary aldosteronism: evidence against a second epidemic.
J Hypertens. 2012 Oct;30(10):1899-902. doi: 10.1097/HJH.0b013e3283559a03.
4
Emergence and evolution of the renin-angiotensin-aldosterone system.
J Mol Med (Berl). 2012 May;90(5):495-508. doi: 10.1007/s00109-012-0894-z. Epub 2012 Apr 14.
5
Resistant hypertension and aldosterone: an update.
Can J Cardiol. 2012 May;28(3):318-25. doi: 10.1016/j.cjca.2012.03.010. Epub 2012 Apr 21.
6
Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies.
Eur J Endocrinol. 2012 Jul;167(1):7-15. doi: 10.1530/EJE-11-1013. Epub 2012 Apr 10.
7
Recent advancements in the treatment of resistant hypertension.
Postgrad Med. 2012 Jan;124(1):67-73. doi: 10.3810/pgm.2012.01.2519.
8
Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
Am J Hypertens. 2012 May;25(5):514-23. doi: 10.1038/ajh.2011.245. Epub 2012 Jan 19.
9
Acute and chronic regulation of aldosterone production.
Mol Cell Endocrinol. 2012 Mar 24;350(2):151-62. doi: 10.1016/j.mce.2011.07.034. Epub 2011 Aug 4.
10
Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community.
Eur J Cardiovasc Prev Rehabil. 2011 Aug;18(4):664-73. doi: 10.1177/1741826710389406. Epub 2011 Feb 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验